

This Week's Citation Classic

CC/NUMBER 2
JANUARY 10, 1983

Hamberg M, Svensson J & Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. *Proc. Nat. Acad. Sci. US* 72:2994-8, 1975. [Department of Chemistry, Karolinska Institutet, Stockholm, Sweden]

Stimulation of human blood platelets results in the formation of thromboxane A₂ from platelet arachidonic acid. Thromboxane A₂ in very low concentrations causes clumping of human platelets and has a mediator role in hemostasis and in the generation of vascular disease. [The SCI® indicates that this paper has been cited in over 1,305 publications since 1975.]

Mats Hamberg
Department of Chemistry
Karolinska Institutet
S-104 01 Stockholm 60
Sweden

November 10, 1982

"The discovery of the thromboxane family of compounds in 1974-1975 can be regarded as a logical outcome of our previous work on the mechanism of prostaglandin biosynthesis from certain polyunsaturated fatty acids carried out from 1965 to 1967.^{1,2} This work led to the proposal of the existence of endoperoxide intermediates; however it was not until 1973 that such intermediates (prostaglandins G₂ and H₂) could be isolated.³ The access to pure endoperoxides and the finding of their pro-aggregated activity on human blood platelets³ necessitated a study on the metabolic fate of arachidonic acid in human platelets⁴ and also made possible the work by Moncada and Vane which led to the discovery of prostaglandin I₂ (prostacyclin).⁵

"In platelets, two pathways of arachidonic acid metabolism were found. One was initiated by a novel lipoxygenase and resulted in the formation of 12-hydroxyeicosatetraenoic acid. This was the first example of a lipoxygenase-catalyzed reaction in animal tissue. Subsequently, several other lipoxygenases catalyzing dioxygenation of polyunsaturated fatty acids were found in animal tissue. Of special interest is arachidonic acid 5-

lipoxygenase which catalyzes the first reaction in the formation of leukotrienes.⁶

"The second pathway of arachidonic acid metabolism in the platelets was initiated by the aspirin-sensitive enzyme, fatty acid cyclooxygenase, and resulted in the formation of thromboxane B₂ and a monohydroxy acid.⁴ These two compounds were also formed from prostaglandin endoperoxides. The relatively complicated non-prostanoate structure of thromboxane B₂ suggested that its formation from prostaglandin endoperoxides occurred by more than one reaction. An intermediate having a fused oxetane-oxane ring structure appeared especially attractive. By a number of chemical studies including trapping experiments with nucleophilic agents, we were able to confirm the presence of an oxetane-oxane structure in the intermediate and to elucidate its complete chemical structure. The compound was called thromboxane A₂ and was found to be very unstable in aqueous medium (t_{1/2} = 30 sec at 37°).

"At the same time, in collaboration with J. Svensson, who was carrying out his doctoral work at the department of chemistry, we observed a transient formation of very unstable potent pro-aggregating material upon incubation of platelet suspensions with arachidonic acid. This material was identified as thromboxane A₂ on the basis of its formation from prostaglandin endoperoxides, instability in aqueous medium, etc.

"Formation and action of thromboxane A₂ is the first example of physiological and pathological roles for the prostaglandin-thromboxane system in man. The finding of a new endogenously formed mediator in hemostasis and in the generation of vascular disease has stimulated a large number of biochemical, physiological, and clinical studies. This, I think, is the reason for the frequent citation of our paper."

1. **Samuelsson B.** On the incorporation of oxygen in the conversion of 8,11,14-eicosatrienoic acid into prostaglandin E₁. *J. Amer. Chem. Soc.* 87:3011-13, 1965.
2. **Hamberg M & Samuelsson B.** On the mechanism of the biosynthesis of prostaglandins E₁ and F_{1α}. *J. Biol. Chem.* 242:5336-43, 1967.
3. **Hamberg M, Svensson J, Wakabayashi T & Samuelsson B.** Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. *Proc. Nat. Acad. Sci. US* 71:345-9, 1974. [The SCI indicates that this paper has been cited in over 790 publications since 1974.]
4. **Hamberg M & Samuelsson B.** Novel transformations of arachidonic acid in human platelets. *Proc. Nat. Acad. Sci. US* 71:3400-4, 1974. [The SCI indicates that this paper has been cited in over 790 publications since 1974.]
5. **Moncada S, Gryglewki R, Bunting S & Vane J R.** An enzyme isolated from arteries transforms prostaglandin endoperoxides into an unstable substance that inhibits platelet aggregation. *Nature* 263:663-5, 1976. [The SCI indicates that this paper has been cited in over 1,260 publications since 1976.]
6. **Samuelsson B.** The leukotrienes: an introduction. (Samuelsson B & Paoletti R, eds.) *Leukotrienes and other lipoxygenase products.* New York: Raven Press, 1982. p. 1-17.